Limits...
Clinical and Endoscopic Features of Metastatic Tumors in the Stomach.

Kim GH, Ahn JY, Jung HY, Park YS, Kim MJ, Choi KD, Lee JH, Choi KS, Kim do H, Lim H, Song HJ, Lee GH, Kim JH - Gut Liver (2015)

Bottom Line: Twelve patients received treatments after the diagnosis of gastric metastasis.The median survival period from the diagnosis of gastric metastasis was 3.0 months (interquartile range, 1.0 to 11.0 months).Patients with solitary lesions and patients who received any treatments survived longer after the diagnosis of metastatic cancer than patients with multiple lesions and patients who did not any receive any treatments.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, and Asan Digestive Disease Research Institute, Seoul, Korea.

ABSTRACT

Background/aims: Metastasis to the stomach is rare. The aim of this study was to describe and analyze the clinical outcomes of cancers that metastasized to the stomach.

Methods: We reviewed the clinicopathological aspects of patients with gastric metastases from solid organ tumors. Thirty-seven cases were identified, and we evaluated the histology, initial presentation, imaging findings, lesion locations, treatment courses, and overall patient survival.

Results: Endoscopic findings indicated that solitary lesions presented more frequently than multiple lesions and submucosal tumor-like tumors were the most common appearance. Malignant melanoma was the tumor that most frequently metastasized to the stomach. Twelve patients received treatments after the diagnosis of gastric metastasis. The median survival period from the diagnosis of gastric metastasis was 3.0 months (interquartile range, 1.0 to 11.0 months). Patients with solitary lesions and patients who received any treatments survived longer after the diagnosis of metastatic cancer than patients with multiple lesions and patients who did not any receive any treatments.

Conclusions: Proper treatment with careful consideration of the primary tumor characteristics can increase the survival period in patients with tumors that metastasize to the stomach, especially in cases with solitary metastatic lesions in endoscopic findings.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier survival curves of (A) patients who underwent chemotherapy, surgery, or radiotherapy versus patients who underwent conservative treatment (p<0.001); and (B) patients with solitary versus multiple tumors (p=0.047).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562778&req=5

f2-gnl-09-615: Kaplan-Meier survival curves of (A) patients who underwent chemotherapy, surgery, or radiotherapy versus patients who underwent conservative treatment (p<0.001); and (B) patients with solitary versus multiple tumors (p=0.047).

Mentions: Among the 12 patients who received treatment, the median survival period after the diagnosis of metastatic cancer and the median survival period after the diagnosis of primary cancer were longer than the 25 patients who did not receive treatment (11.0 months [IQR, 9.0 to 30.0 months] vs 2.0 months [IQR, 1.0 to 11.0 months, p<0.001]; 60.0 months [IQR, 18.0 to 85.0 months] vs 14.0 months [IQR, 5.0 to 32.0 months], respectively; p=0.022) (Fig. 2A).


Clinical and Endoscopic Features of Metastatic Tumors in the Stomach.

Kim GH, Ahn JY, Jung HY, Park YS, Kim MJ, Choi KD, Lee JH, Choi KS, Kim do H, Lim H, Song HJ, Lee GH, Kim JH - Gut Liver (2015)

Kaplan-Meier survival curves of (A) patients who underwent chemotherapy, surgery, or radiotherapy versus patients who underwent conservative treatment (p<0.001); and (B) patients with solitary versus multiple tumors (p=0.047).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562778&req=5

f2-gnl-09-615: Kaplan-Meier survival curves of (A) patients who underwent chemotherapy, surgery, or radiotherapy versus patients who underwent conservative treatment (p<0.001); and (B) patients with solitary versus multiple tumors (p=0.047).
Mentions: Among the 12 patients who received treatment, the median survival period after the diagnosis of metastatic cancer and the median survival period after the diagnosis of primary cancer were longer than the 25 patients who did not receive treatment (11.0 months [IQR, 9.0 to 30.0 months] vs 2.0 months [IQR, 1.0 to 11.0 months, p<0.001]; 60.0 months [IQR, 18.0 to 85.0 months] vs 14.0 months [IQR, 5.0 to 32.0 months], respectively; p=0.022) (Fig. 2A).

Bottom Line: Twelve patients received treatments after the diagnosis of gastric metastasis.The median survival period from the diagnosis of gastric metastasis was 3.0 months (interquartile range, 1.0 to 11.0 months).Patients with solitary lesions and patients who received any treatments survived longer after the diagnosis of metastatic cancer than patients with multiple lesions and patients who did not any receive any treatments.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, and Asan Digestive Disease Research Institute, Seoul, Korea.

ABSTRACT

Background/aims: Metastasis to the stomach is rare. The aim of this study was to describe and analyze the clinical outcomes of cancers that metastasized to the stomach.

Methods: We reviewed the clinicopathological aspects of patients with gastric metastases from solid organ tumors. Thirty-seven cases were identified, and we evaluated the histology, initial presentation, imaging findings, lesion locations, treatment courses, and overall patient survival.

Results: Endoscopic findings indicated that solitary lesions presented more frequently than multiple lesions and submucosal tumor-like tumors were the most common appearance. Malignant melanoma was the tumor that most frequently metastasized to the stomach. Twelve patients received treatments after the diagnosis of gastric metastasis. The median survival period from the diagnosis of gastric metastasis was 3.0 months (interquartile range, 1.0 to 11.0 months). Patients with solitary lesions and patients who received any treatments survived longer after the diagnosis of metastatic cancer than patients with multiple lesions and patients who did not any receive any treatments.

Conclusions: Proper treatment with careful consideration of the primary tumor characteristics can increase the survival period in patients with tumors that metastasize to the stomach, especially in cases with solitary metastatic lesions in endoscopic findings.

No MeSH data available.


Related in: MedlinePlus